Equities

Shin Nippon Biomedical Laboratories Ltd

Shin Nippon Biomedical Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)2,498.00
  • Today's Change113.00 / 4.74%
  • Shares traded2.06m
  • 1 Year change+56.91%
  • Beta0.5874
Data delayed at least 20 minutes, as of Feb 03 2023 06:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.

  • Revenue in JPY (TTM)21.17bn
  • Net income in JPY6.23bn
  • Incorporated1973
  • Employees994.00
  • Location
    Shin Nippon Biomedical Laboratories Ltd28F, St Luke's Tower, 8-1, Akashi-choCHUO-KU 104-0044JapanJPN
  • Phone+81 355655001
  • Fax+81 355656160
  • Websitehttps://www.snbl.co.jp/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
2395:TYO since
announced
Transaction
value
Ina Research IncDeal completed01 Jun 202201 Jun 2022Deal completed51.12%20.97m
Data delayed at least 20 minutes, as of Feb 03 2023 06:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
StemRIM Inc0.00-1.97bn54.57bn44.00--5.98-----33.22-33.220.00152.200.00----0.00-19.82-10.05-20.00-10.24-------84.4486.65-16,696.510.0003---98.36-40.18-234.50------
GNI Group Ltd15.91bn847.96m58.27bn629.0069.482.5444,075.333.6617.6617.66333.11482.410.48051.556.6925,301,370.00-1.502.39-1.633.1785.5685.26-3.116.046.152.920.33980.0029.8457.56-15.26--140.50--
Katakura Industries Co., Ltd.33.88bn1.79bn60.78bn1.06k31.970.830713.191.7953.9953.991,020.072,077.860.24942.725.3331,989,610.001.091.931.482.8436.1536.744.366.372.69--0.147521.11-5.08-4.3272.5223.98-16.809.86
Eiken Chemical Co Ltd45.03bn6.54bn69.01bn745.009.031.199.791.53175.57175.571,208.081,329.460.70612.793.3860,436,240.0010.268.2812.8010.8548.9845.3514.5411.042.43--0.057531.2711.205.2623.2816.3420.5115.33
TORII PHARMACEUTICAL CO., LTD.48.87bn3.99bn89.28bn560.0021.820.736520.101.83142.09142.091,739.264,209.040.37822.732.4187,258,930.003.096.823.377.8549.1451.068.1715.538.03--0.0016.7812.68-4.84-3.463.51-13.220.00
TOWA PHARMACEUTICAL CO., LTD173.86bn9.36bn102.98bn4.08k10.710.70924.400.5923186.62186.623,473.482,818.590.57521.453.6842,633,890.003.105.904.337.8439.1044.125.3910.220.8056--0.51816.486.9214.2814.0123.34-8.5012.47
Shin Nippon Biomedical Laboratories Ltd21.17bn6.23bn104.00bn994.0016.693.6913.454.91149.68149.68508.61676.880.44091.605.9821,301,740.0013.055.0618.917.6553.4345.4829.6014.970.8221--0.37324.1317.460.577894.65--9.71--
KYORIN Holdings, Inc.105.53bn5.05bn107.18bn2.22k18.810.762212.121.0288.1888.181,841.562,176.730.6211.303.0447,491,000.002.973.333.664.0346.1351.064.795.461.87--0.144370.592.56-1.77-35.86-11.650.338-2.16
Zeria Pharmaceutical Co Ltd66.16bn5.90bn110.59bn1.74k15.601.4013.601.67133.42133.421,492.071,489.110.50301.533.5538,087,390.004.503.107.054.9871.9171.288.955.920.79194.670.439645.8712.84-1.7026.032.25-17.521.81
Kissei Pharmaceutical Co Ltd66.93bn12.77bn127.46bn1.83k8.880.579310.211.90276.89276.891,451.394,246.430.28481.682.5036,614,330.005.483.165.983.4248.5855.9819.2310.454.18--0.007834.12-5.31-1.83144.4810.83-5.394.01
Mochida Pharmaceutical Co Ltd109.37bn9.58bn135.74bn1.54k13.370.975511.101.24252.77252.772,899.753,464.880.6782.243.5870,835,500.005.945.227.126.4053.9951.578.757.763.62--0.0040.566.982.5123.084.3921.993.04
Data as of Feb 03 2023. Currency figures normalised to Shin Nippon Biomedical Laboratories Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

13.36%Per cent of shares held by top holders
HolderShares% Held
Asset Management One Co., Ltd.as of 13 Jan 20232.13m5.12%
Nomura Asset Management Co., Ltd.as of 30 Dec 2022643.60k1.55%
The Vanguard Group, Inc.as of 05 Jan 2023502.94k1.21%
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 30 Dec 2022451.90k1.09%
Daiwa Asset Management Co. Ltd.as of 30 Dec 2022384.30k0.92%
Dimensional Fund Advisors LPas of 05 Jan 2023354.40k0.85%
Nikko Asset Management Co., Ltd.as of 06 Jan 2023314.90k0.76%
Goldman Sachs Asset Management Co., Ltd. (Japan)as of 31 Oct 2022294.90k0.71%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 05 Jan 2023257.70k0.62%
BlackRock Fund Advisorsas of 04 Jan 2023226.50k0.54%
More ▼
Data from 30 Sep 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.